- Nachrichtendetail
-
24.04.2024 16:26:17 - dpa-AFX: *IMMUTEP: PHASE IIB TRIAL SHOWS POSITIVE RESULTS IN FIRST-LINE HNSCC TREATMENT WITH EFTILAGIMOD ALPHA
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Merck & Co | A0YD8Q | NYSE | 127,570 | 06.05.24 22:03:25 | +0,060 | +0,05% | 127,410 | 127,650 | 127,180 | 127,510 |
